|Articles|May 29, 2020

ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment

Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.

 

See more ASCRS coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME